Genentech Gets Positive Result in Cancer Trial

Xconomy Boston — 

Lexington, MA-based Curis (NASDAQ:CRIS) said this morning that its partner Genentech of South San Francisco informed the firm that its pivotal Phase II study of a drug dubbed vismodegib in patients with an inoperable form of severe skin cancer called advanced basal cell carcinoma met its primary endpoint of tumor shrinkage. The most common adverse events of the 104-patient trial included muscle spasms, hair loss, altered taste sensation, weight loss, fatigue, nausea, decreased appetite, and diarrhea. Swiss drug giant Roche, the owner of Genentech, has indicated plans to make at least one regulatory submission for approval of the drug in 2011, according to Curis. Curis’ stock was up 14 percent to $3.35 per share as of 10:42 am Eastern time.